1Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia : mechanism of action, efficacy and tolerability. Drugs, 2008; 68 (16): 2269-2292.
2Fowler JA, Bettinger TL, Argo TR. Paliperidone extended - release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther. 2008; 50 (2): 231-248.
4Lieberman JA. Dopamine partial agonists : a new class of antipsychotic. CNS Drugs, 2004; 18 (4) : 251 -267.
5Citrome L. Palipcridone: quo vadis? Int J Clin Pract. 2007; 61 (4) : 653 -662.
6Thyssen A, Crauwels H, Clcton A, et al. Effects of hepatic impairment on the pharmacokinefics ofimmediaterelease paliperidone [poster]. 46th Annual Meeting of the NCEDU ; 2006; Boca Raton (FL), 186.
7Aravagiri M, Marder SR, Nuechterlein KH, et al. lntra - and interindividual variations in steady - state plasma concentrations of risperidone and 9 - hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003 ; 25 (6) : 657 - 664.
8Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9 - hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000; 22 (4) : 481 -485.
9Herbert Y, Melter MD, William V, et al. Efficacy and tolembility of oral pailiperidone extcnded - releaase tablets in the treatment of acute schizophrenia: pooled data from three 6- week, placebocontrolled studies. J Clin Psychiatry, 2008 ; 69 (5): 817-829.
10Marino J, Caballero J. Paliperidone extended - release for the treatment of schizophrenia. Pharmacotherapy, 2008 ; 28 (10): 1283 -1298.
